WO2014167862A1

WO2014167862A1 - Contact lens composition, and contact lens package using same

Info

Publication number: WO2014167862A1
Application number: PCT/JP2014/002067
Authority: WO
Inventors: 治正有田; 和宏辻; 暁清宮; 稔下山; 佑次望月; 祐介竹内
Original assignee: ロート製薬株式会社
Priority date: 2013-04-12
Filing date: 2014-04-10
Publication date: 2014-10-16
Also published as: TW201517938A

Abstract

This contact lens composition includes a vinyl acetate-vinylpyrrolidone copolymer.

Description

Contact lens composition and contact lens package using the same

The present invention relates to a composition for contact lenses, and particularly suitable for use as a packaging solution (packaging solution) enclosed in a packaging container together with the contact lens when the contact lens is sealed in a container and packaged. The present invention relates to a contact lens composition and a contact lens package (packaged contact lens product) using the same. Furthermore, the present invention relates to a method for manufacturing a contact lens.

Since the contact lens is a medical device that is directly inserted into the eye, proteins caused by tears and eyelids are adsorbed on the contact lens and become dirty during wearing.

Further, such contact lens dirt causes a decrease in the transparency of the lens and deteriorates the wettability of the lens surface. In addition, when a contact lens that is contaminated is used, the eyes are irritated and a foreign body sensation is generated, causing inflammation and damage.

Therefore, a contact lens has been proposed to suppress such contamination due to protein adsorption. More specifically, the phosphorylcholine group is shared on the surface of the ophthalmic lens material by, for example, post-treatment of reacting the phosphorylcholine group-containing compound with the ophthalmic lens material instead of polymerizing the phosphorylcholine group-containing monomer on the surface of the contact lens. A bonded contact lens material is disclosed. Further, it is described that a contact lens having an excellent protein adsorption preventing effect can be provided because a sufficient phosphorylcholine group can be introduced by producing a contact lens using such a material. (For example, refer to Patent Document 1).

Also disclosed is a surface-treated contact lens in which an ethylene oxide derivative is immobilized on the surface of the contact lens. And it is described that by using such a contact lens, high hydrophilicity and protein suppression effect can be obtained over a long period of time (see, for example, Patent Document 2).

Japanese Patent No. 3715308 JP 2005-309228 A

However, in the contact lens material described in Patent Document 1, a step of producing a phosphorylcholine group-containing compound to be introduced, a step of polymerizing the contact lens material, and introducing a hydroxyl group by performing plasma treatment on the surface of the contact lens And a step of introducing a phosphorylcholine group into the hydroxyl group of the contact lens is required, which causes a problem that the manufacturing process of the contact lens becomes complicated.

Further, the contact lens described in Patent Document 2 also has a problem that the manufacturing process of the contact lens becomes complicated because it is necessary to perform radiation irradiation in a state where the ethylene oxide derivative is in contact with the contact lens.

Further, in the contact lens described in Patent Document 1, since the phosphorylcholine group-containing compound has a charge, the adsorption of lysozyme, which is a cationic tear fluid protein, is promoted, and the protein adsorption is effective. There is a problem that it is difficult to suppress it. In addition, when eye drops are worn while wearing contact lenses, or when disinfecting and washing is performed after wearing contact lenses, cations and anions of eye drops and disinfectants are adsorbed, which becomes a risk factor for eye damage.

Therefore, the present invention has been made in view of the above-described problems, and a contact lens composition capable of suppressing protein adsorption to a lens and a contact lens package using the same without performing complicated processing. The purpose is to provide.

In order to achieve the above object, the composition for contact lenses of the present invention is characterized by containing a vinyl acetate-vinyl pyrrolidone copolymer.

According to this configuration, since it contains a vinyl acetate-vinylpyrrolidone copolymer, the contact lens composition of the present invention can be complicated by using it as a packaging solution sealed in a packaging container together with the contact lens. It is possible to enhance the protein adsorption suppression effect on the contact lens without performing any special treatment. In addition, even when used in the form of eye drops for contact lenses, eye washes, contact lens mounting liquids, contact lens care agents, etc., protein adsorption on the contact lenses can be suppressed.

Especially, even when proteins and lipids coexist like tears, it is possible to enhance the protein adsorption suppression effect on contact lenses.

According to the present invention, it is possible to suppress protein adsorption to the lens without performing complicated processing.

Further, according to the present invention, it becomes possible to suppress the adsorption of lipid to the contact lens. In addition, according to the present invention, it is possible to suppress friction of the contact lens on the eye surface. In addition, according to the present invention, the feeling of dryness when wearing contact lenses, the feeling of pinching of eyelids at the time of blinking, the feeling that the lens pulls up, the discomfort such as foreign body feeling, etc. are improved and moistened and comfortable for a long time after wearing. It is possible to provide a contact lens that exhibits a good feeling of use. Furthermore, according to the present invention, it is possible to promote the expression of membrane-type mucin in the corneal epithelium, reduce dryness and discomfort caused by wearing contact lenses, and improve the moist feeling when wearing contact lenses. .

It is a figure for demonstrating the manufacturing process of the contact lens package using the composition for contact lenses of this invention.

The contact lens composition of the present invention is used as a packaging solution (packaging solution) sealed in a packaging container together with the contact lens when the contact lens is sealed in a container and packaged.

The contact lens composition of the present invention is characterized by containing a vinyl acetate-vinyl pyrrolidone copolymer, and further preferably contains a cooling agent, a surfactant, or a buffer.

(Vinyl acetate-vinyl pyrrolidone copolymer)
In the present invention, a vinyl acetate-vinyl pyrrolidone copolymer represented by the following formula (1) is used.

(In the formula, n is an integer of 20 to 1200, and m is an integer of 40 to 1600.)

By using such a vinyl acetate-vinylpyrrolidone copolymer, it is possible to enhance the protein adsorption inhibiting effect on the contact lens.

Further, the ratio (mass ratio) of vinyl acetate / vinyl pyrrolidone in the vinyl acetate-vinyl pyrrolidone copolymer is not particularly limited, but the viewpoint of enhancing the protein adsorption inhibitory effect and the viewpoint of increasing the solubility in a solvent such as water or ethanol. From the above, the upper limit is preferably 90/10 or less, more preferably 80/20 or less, more preferably 70/30 or less, improving the protein adsorption inhibitory effect and solubility in solvents such as water and ethanol, and contact lenses. From the viewpoint of improving the clarity of the film, 60/40 or less is particularly preferable, 50/50 or less is more preferable, and 40/60 or less is most preferable. Further, the lower limit is preferably 10/90 or more, more preferably 20/80 or more, and particularly preferably 30/70 or more from the viewpoint that the protein adsorption suppressing effect is more remarkably exhibited.

In the present invention, these upper limit value and lower limit value can be arbitrarily combined.

The specific ratio (mass ratio) of vinyl acetate / vinyl pyrrolidone is 90/10 to 10/90, preferably 80/20 to 20/80, more preferably 80/20 to 30/70, still more preferably 60. / 40 to 30/70, particularly preferably 50/50 to 30/70, and still more preferably 40/60 to 30/70. In particular, 60/40 to 30/70 are exemplified from the viewpoint of enhancing the protein adsorption inhibitory effect, the viewpoint of enhancing the solubility in a solvent such as water or ethanol, and the viewpoint of enhancing the clarity of the contact lens.

Further, from the viewpoint of surely exerting the protein adsorption suppressing effect without improving the cost, the concentration of the vinyl acetate-vinylpyrrolidone copolymer in the contact lens composition is set to a lower limit of 0. 0001 (w / v)% or more, preferably 0.001 (w / v)% or more, more preferably 0.01 (w / v)% or more, particularly 0.05 (w / v)% or more. preferable. The upper limit is 10 (w / v)% or less, preferably 3 (w / v)% or less, more preferably 1 (w / v)% or less, and 0.1 (w / v)% or less. Particularly preferred.

The specific concentration range is 0.0001 to 10 (w / v)%, preferably 0.001 to 3 (w / v)%, more preferably 0.01 to 3 (w / v)%. 0.01 to 1 (w / v)% is more preferable, 0.05 to 1 (w / v)% is still more preferable, and 0.05 to 0.1 (w / v)% is most preferable.

The weight average molecular weight of the vinyl acetate-vinyl pyrrolidone copolymer is not particularly limited. From the viewpoint of having a molecular size that can enter a matrix of a contact lens material and coat a group that easily adsorbs a protein, 5000 to 500,000. Is preferably 10,000 to 200,000, and more preferably 20,000 to 100,000.

The “weight average molecular weight” referred to here is a weight average molecular weight measured using GPC-MALS, and the measurement conditions are as follows.

Column: 2 TSKgel GMPW _XL Eluent: 0.1 mol / L sodium nitrate aqueous solution / acetonitrile = 8/2
One kind of vinyl acetate-vinylpyrrolidone copolymer may be used alone, or two or more kinds may be used in combination.

(Cooling agent)
The contact lens composition of the present invention preferably further contains a cooling agent. The refreshing agent generally gives a refreshing feeling to the eyes. However, the refreshing agent of the present invention also has a role of eliminating foreign material feeling and itchiness when wearing the lens. In the present invention, terpenoids such as menthol, menthone, camphor, borneol, geraniol, cineol, citronellol, carvone, anethole, eugenol, limonene, linalool, linalyl acetate, and derivatives thereof are used. These compounds may be d-form, l-form or dl-form.

Of these refreshing agents, terpenoids such as menthol, menthone, camphor, borneol, and geraniol are preferred, and examples of essential oils containing these include cool mint, peppermint oil, peppermint oil, camphor oil, and rose oil. The

More specifically, when menthol or camphor is used, it is preferable to use l-menthol, dl-menthol, d-camphor and dl-camphor, and l-menthol, d-camphor and dl-camphor are preferred. More preferred is l-menthol.

Further, from the viewpoint of suppressing the irritation to the eyes and ensuring a refreshing feeling, the concentration of the refreshing agent in the composition for contact lenses is 0.0001 to 0.1 (w / v)% in total. Preferably, 0.0001 to 0.05 (w / v)% is more preferable, 0.0002 to 0.02 (w / v)% is more preferable, and 0.0005 to 0.005 (w / v)% is more preferable. Particularly preferred. In addition, when using the essential oil containing a terpenoid, it can set so that the terpenoid in the essential oil contained in an aqueous composition may satisfy | fill the said content.

In addition, a refreshing agent may be used individually by 1 type, and may be used in combination of 2 or more types.

In general, a dry feeling tends to occur in proportion to the amount of protein adsorbed to the contact lens. However, in the composition for contact lenses of the present invention, the above-mentioned vinyl acetate-vinylpyrrolidone copolymer can be used for contact lenses. Protein adsorption is suppressed, and the dry feeling is reduced. Further, by adding a cooling agent, the dry feeling is further reduced.

Mucin is a mucopolysaccharide expressed on the ocular surface mucosa, and has the function of improving the wettability of the ocular surface by increasing the affinity between the lipid-soluble cell surface and tears, and it is also useful for dry eye patients. Since there are cases where mucin expression is reduced, it is widely known that the decrease in mucin expression correlates with dryness.

In addition, wearing contact lenses destroys the tear structure formed on the surface of the eye, and tear evaporation increases, which causes discomfort such as dryness. Therefore, it can be said that the increase in mucin expression is important from the viewpoint of reducing discomfort during contact lens wearing.

In the contact lens composition of the present invention, the expression level of mucin is dramatically increased by the above-described vinyl acetate-vinylpyrrolidone copolymer and terpenoids such as menthol. A feeling of dryness can be reduced.

(Surfactant)
The contact lens composition of the present invention preferably further contains a surfactant. The surfactant is used to swell the dry contact lens material and improve the releasability from the lens molding die in the contact lens manufacturing process. In addition, the surfactant prevents adhesion of the contact lens to the resin forming the packaging container, improves lubricity and wettability when wearing the contact lens, and improves the solubility of the components used in the contact lens composition. It is for raising. In the contact lens composition of the present invention, a nonionic surfactant, an amphoteric surfactant, a cationic surfactant, or an anionic surfactant is used.

More specifically, as the nonionic surfactant, monolauric acid POE (20) sorbitan (polysorbate 20), monopalmitic acid POE (20) sorbitan (polysorbate 40), monostearic acid POE (20) sorbitan (polysorbate) 60), POE sorbitan fatty acid esters such as tristearic acid POE (20) sorbitan (polysorbate 65), monooleic acid POE (20) sorbitan (polysorbate 80), poloxamer 407, poloxamer 235, poloxamer 188, poloxamer 403, poloxamer 237, POE / POP block copolymers such as Poloxamer 124, POE hydrogenated castor oils such as POE (60) hydrogenated castor oil (polyoxyethylene hydrogenated castor oil 60), POE (35) POE castor oil such as POE (10) castor oil, POE alkyl ethers such as POE (9) lauryl ether, POE-POP alkyl ethers such as POE (20) POP (4) cetyl ether, and POE ( 10) POE alkylphenyl ethers such as nonylphenyl ether, and polyethylene glycol monostearate such as polyoxyl 40 stearate. In addition, the above-mentioned POE shows polyoxyethylene and POP shows polyoxypropylene, and the number in the above-mentioned parenthesis shows the added mole number.

In addition, examples of the amphoteric surfactant include alkyldiaminoethylglycine, and examples of the cationic surfactant include benzalkonium chloride and benzethonium chloride. Examples of the anionic surfactant include alkylbenzene sulfonate, alkyl sulfate, polyoxyethylene alkyl sulfate, aliphatic α-sulfomethyl ester, and α-olefin sulfonic acid.

Further, from the viewpoint of providing sufficient swelling in the contact lens manufacturing process and sufficient lubricity during wearing, the surfactant is preferably a nonionic surfactant, and monooleic acid POE (20) sorbitan (Polysorbate 80), POE / POP block copolymers (for example, Poloxamer 407), POE (40) hydrogenated castor oil (polyoxyethylene hydrogenated castor oil 40), POE (60) hydrogenated castor oil (polyoxyethylene hydrogenated castor oil) 60), POE (35) castor oil (polyoxyethylene castor oil 35), and polyoxyl 40 stearate, monooleic acid POE (20) sorbitan (polysorbate 80), POE (60) hydrogenated castor oil (polyoxyethylene) Hardened castor oil 60) and poloxamer 407 are particularly preferred That's right. From the same viewpoint, the concentration of the surfactant in the contact lens composition is preferably 0.005 to 5 (w / v)%, more preferably 0.01 to 2 (w / v)%, 0.05 to 0.5 (w / v)% is particularly preferable.

In addition, surfactant may be used individually by 1 type and may be used in combination of 2 or more types.

(Buffering agent)
The contact lens composition of the present invention preferably further contains a buffer. The buffering agent is for imparting a buffering action to the ophthalmic composition and for providing formulation stability. In the contact lens composition of the present invention, for example, boric acid buffering agent, phosphoric acid Buffering agents, citrate buffers, acetate buffers and the like can be used.

More specifically, as the borate buffer, boric acid or borate salts such as alkali metal borate and alkaline earth metal borate can be used. Examples of the phosphate buffer include , Phosphoric acid, or phosphates such as alkali metal phosphates and alkaline earth metal phosphates. Further, from the viewpoint of more prominently achieving the effects of the present invention, the buffer is preferably a borate buffer or a phosphate buffer, and boric acid or a salt thereof (sodium borate, potassium tetraborate, potassium metaborate, boron Ammonium phosphate, borax, etc.), phosphoric acid or its salts (disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, trisodium phosphate, dipotassium phosphate, calcium monohydrogen phosphate, phosphoric acid Calcium dihydrogen and the like) are preferred, and phosphoric acid or a salt thereof is more preferred.

The concentration of the buffering agent in the contact lens composition can be appropriately changed depending on the type of the buffering agent and the other compounding components such as vinyl acetate-vinylpyrrolidone. The contact lens of the present invention In the composition for use, 0.01 to 10 (w / v)% is preferable, 0.05 to 5 (w / v)% is more preferable, and 0.1 to 2 (w / v)% is particularly preferable.

In addition, a buffering agent may be used individually by 1 type, and may be used in combination of 2 or more types. In the contact lens composition of the present invention, the pH is adjusted to a range of about 5.5 to 8.5 using the above-mentioned buffer.

(Other ingredients)
The contact lens composition of the present invention may contain an aqueous solvent such as an isotonic agent, a drug, a thickener, a chelating agent, a stabilizer, a pH adjuster, and water in addition to the above-described components. it can. These components may be used individually by 1 type, and may be used in combination of 2 or more types.

For example, tonicity agents include sodium chloride, potassium chloride, glycerin, propylene glycol, glucose, mannitol, sorbitol, boric acid, borax and the like. Further, from the viewpoint of making the tear fluid isotonic while controlling the swelling of the contact lens material, sodium chloride and potassium chloride are preferable, and sodium chloride is particularly preferable. From the same viewpoint, the concentration of the tonicity agent in the contact lens composition is preferably 0.05 to 10 (w / v)%, more preferably 0.2 to 5 (w / v)%. 0.5 to 2 (w / v)% is particularly preferable.

Thickeners include gum arabic powder, sodium alginate, propylene glycol alginate, sodium chondroitin sulfate, sorbitol, dextran 70, tragacanth powder, methylcellulose, carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, carboxyvinyl polymer, polyvinyl alcohol, polyvinyl Examples include pyrrolidone and macrogol 4000.

Chelating agents include edetic acid, edetates (disodium edetate, disodium calcium edetate, trisodium edetate, tetrasodium edetate), nitrilotriacetic acid and its salts, trihydroxymethylaminomethane, sodium hexametaphosphate Citric acid and the like.

Examples of the stabilizer include the above-mentioned edetic acid and edetates, sodium bisulfite, and the like.

The pH of the contact lens composition according to the present embodiment is not particularly limited as long as it is within a range that is pharmaceutically, pharmacologically (pharmaceutically), or physiologically acceptable. The pH of the contact lens composition according to the present embodiment may be, for example, 4.0 to 9.5, preferably 5.0 to 9.0, and 6.0 to 8.5. More preferably, it is more preferably 7.0 to 8.0.

The contact lens composition according to the present embodiment can be adjusted to an osmotic pressure ratio within a range that is acceptable to a living body, if necessary. The appropriate osmotic pressure ratio varies depending on the application site, dosage form, etc., but can be, for example, 0.7 to 5.0, preferably 0.9 to 3.0, preferably 0.9 to 2.0. More preferably. The osmotic pressure can be adjusted by a known method in the technical field using an inorganic salt, a polyhydric alcohol, or the like. The osmotic pressure ratio is the ratio of the osmotic pressure of the sample to 286 mOsm (0.9 w / v% sodium chloride aqueous solution) based on the 16th revised Japanese Pharmacopoeia. Measure with reference to (freezing point depression method). The standard solution for osmotic pressure ratio measurement (0.9 w / v% sodium chloride aqueous solution) was prepared by drying sodium chloride (Japanese Pharmacopoeia standard reagent) at 500 to 650 ° C. for 40 to 50 minutes, and then in a desiccator (silica gel). The solution is allowed to cool and 0.900 g is accurately weighed and dissolved in purified water to prepare exactly 100 mL, or a commercially available standard solution for osmotic pressure ratio measurement (0.9 w / v% sodium chloride aqueous solution) can be used.

Examples of the pH regulator include sodium hydroxide, potassium hydroxide, hydrochloric acid, sulfuric acid, acetic acid and the like.

(Production method)
It does not specifically limit as a manufacturing method of the composition for contact lenses of this invention, It carries out by the method generally implemented by those skilled in the art. For example, it can be obtained by adding the above-described components to sterilized purified water or the like so as to have a predetermined concentration, uniformly dissolving, and adjusting the pH. Thereafter, a packaging container (blister pack) made of polyethylene, polypropylene, or the like is filled together with the contact lens, and sterilized by an autoclave or the like.

(contact lens)
The contact lens to which the composition for contact lenses of the present invention is applied is not particularly limited, and can be applied to all contact lenses including soft contact lenses and hard contact lenses. In particular, the soft contact lens may be a hydrous soft contact lens using hydrogel (hydrogel contact lens), or a water-free non-hydrous soft contact lens using a copolymer of butyl acrylate and butyl methacrylate. .

The hydrogel contact lens may be a silicone hydrogel contact lens in which silicone is mixed with hydrogel, or a non-silicone hydrogel contact lens in which silicone is not mixed.

Further, as the hydrogel contact lens, a lens containing 2-hydroxyethyl methacrylate (HEMA) as the hydrogel is preferable.

Further, the contact lens composition of the present invention can be applied to any soft contact lens classified into groups I to IV in the soft contact lens classification according to US Food and Drug Administration (FDA) standards.

Specific examples of contact lenses include alphafilcon, asamofilcon, balafilcon, etafilcon, hefilcon, hilafilcon, lidofilcon (lidofilcon) , Lotrafilcon, metafilcon, nerfilcon, ocufilcon, omafilcon, femfilcon, polyconte, tecon, tecon, filcon tetrafilcon), vasafilcon (vasurfil) on), bifilcon, senofilcon, galifilcon, enfilcon, comfilcon, narafilcon, defilcon, filcon, efilcon Illustrated as II-3.

In particular, contact lenses belonging to soft contact lens classification group II (water content of 50% or more, nonionic) according to US Food and Drug Administration (FDA) standards (for example, Omafilcon A in United States States (Approved Names), Alpha filcon A, Hirafilcon A, B, Nelfilcon A, Vasafilcon A) and contact lenses belonging to soft contact lens classification group IV (moisture content is 50% or more, ionic) (for example, United States certification name (United States Ettafilcon A, Metafilcon A, Metafilcon B, Ocufilcon A, Ocufilcon B, Ocufilcon C, Ocufilcon D, Ocufilcon E, Femfilcon A, Bifilcon A) in Approved Names) Played more prominently , It can be preferably used. Further, among contact lenses belonging to the soft contact lens classification group II, Omafilcon A is more preferable, and among the soft contact lens classification groups IV, etafilcon A is more preferable. Particularly preferred are soft contact lens group IV lenses, and particularly preferred is etafilcon A.

Here, ionic means that the content of the ionic component in the contact lens is 1 mol% or more, and nonionic means that the content of the ionic component in the contact lens is less than 1 mol%. To tell.

From another point of view, the composition for contact lenses of the present invention has an effect of suppressing the adsorption of lipids to the contact lenses, and therefore can be suitably used for silicone hydrogel contact lenses that easily adsorb lipids. it can. In addition, a silicone hydrogel contact lens is preferable from the viewpoint that the friction suppressing effect on the contact lens surface, which is one of the effects of the present invention, can be effectively expressed.

In addition, among the silicone hydrogel lenses, from the viewpoint that the effect of the present application is more prominently produced, Cenofilcon, Garifilcon, Lotrafilcon, Balafilcon, Enfilcon, Comfilcon, Narafilcon, Derefilcon, Efrofilcon, Asmofilcon and FILICON II II-3 are preferred, senofilcon, galifilcon, lotafilcon, barafilcon, enfilcon, comfilcon, and narafilcon are more preferred, and senofilcon, lotafilcon, and barafilcon are particularly preferred.

Further, from the viewpoint of prominently exerting the lipid adsorption effect, senofilcon, galifircon, narafilcon, and FILICON II II are preferable, senofilcon, galifircon, and narafilcon are more preferable, and senofilcon A, galifircon A, and narafircon A are preferable. Further preferred is senofilcon A, particularly preferred.

In addition, from the viewpoint of prominently suppressing the friction, Senofilcon, Garifilcon, Lotrafilcon, Balafilcon, Enfilcon, Comfilcon, Narafilcon, FILICON II 3 are preferable, and Lotrafilcon, Balafilcon, Enfilcon, Com Filcon is preferable, and Lotrafilcon A, Lotrafilcon B, and Rosefilcon A are particularly preferable.

Examples of the types of contact lenses to which the contact lens composition of the present invention is applied include one-day disposable contact lenses (daily disposable lenses), frequent replacement lenses (for example, every 14 days), disposable wearable contact lenses ( Disposable contact lenses such as every week) or conventional lenses (including regular replacement soft contact lenses) may be used. In particular, in the method of the present invention, since a desired effect can be obtained at a low cost, it is particularly necessary to reduce the manufacturing cost as a contact lens, and the effect of the present application can be exhibited more remarkably. From the viewpoint, a disposable contact lens is preferable, a one-day disposable contact lens, a frequent replacement lens, and a disposable contact lens for continuous wear are more preferable, and a one-day disposable contact lens is particularly preferable.

(Method of manufacturing contact lens package)
Next, an example of the manufacturing method of the contact lens package using the composition for contact lenses is demonstrated. FIG. 1 is a diagram for explaining a manufacturing process of a contact lens package using the composition for contact lenses of the present invention, and is an example in which the composition for contact lenses is used as a package liquid for contact lenses. .

In addition, the manufacturing method of a contact lens is not limited to the method shown below, What kind of method may be used if it is a conventionally well-known method.

First, the raw material monomers (for example, 2-hydroxyethyl methacrylate, methyl methacrylate, N-vinylpyrrolidone, tris and bis (trimethylsilyloxy) silylalkylglycerol methacrylate), cross-linking agents (for example, ethylene glycol dimethacrylate, 4-vinylbenzyl) Methacrylate), polymerization initiators (for example, azobisisobutyronitrile, methyl orthobenzoyl benzoate), colorants (for example, anthraquinone colorants, phthalocyanine colorants), UV absorbers (for example, benzophenone-based polymerizable UV absorbers) Agent, benzotriazole-based UV absorber) and the like are mixed to prepare a compound for contact lenses.

Next, as shown in FIG. 1B, a lens molding die 4 comprising a female molding die 2 and a male molding die 3 is prepared, and as shown in FIG. The prepared contact lens composition 5 is injected into the concave surface 2 a formed on the mold 2. As the lens molding die 4, for example, a polypropylene die can be used.

Next, as shown in FIGS. 1B and 1C, the female mold 2 and the male mold 3 are aligned, and the concave surface 2a of the female mold 2 and the male mold are formed. A contact lens compound 5 is placed in a cavity formed between the convex surface 3 a of the mold 3.

Next, as shown in FIG. 1C, a contact lens is manufactured by irradiating the lens molding die 4 with ultraviolet rays 6 using, for example, a mercury lamp to perform photopolymerization.

In addition, it is good also as a structure which manufactures a contact lens by putting the lens shaping | molding die 4 in a furnace and performing heat processing for a predetermined time at predetermined temperature instead of performing photopolymerization by ultraviolet irradiation.

Next, as shown in FIG. 1 (d), the female mold 2 and the male mold 3 are separated, and the contact lens 1 is separated from the female mold 2. At this time, the contact lens 1 can be easily separated by using the above-described mold made of polypropylene. In addition, if a large amount of unreacted monomer is present, it may be difficult to separate the contact lens 1. For example, the unreacted monomer is removed by a method such as immersion in an excessive amount of packaging solution or physiological saline. May be.

Next, for example, the above-mentioned vinyl acetate-vinyl pyrrolidone, a cooling agent, a surfactant, a buffering agent and the like are added to and dissolved in sterilized purified water, and the pH is adjusted. As shown in FIG.1 (e), the thing 7 is filled into the packaging container 8 formed with the polypropylene etc. As shown in FIG.

Then, the contact lens 1 described above is immersed in the contact lens composition 7 in the packaging container 8, the contact lens 1 and the contact lens composition 7 are brought into contact with each other, and the contact lens 1 and the contact lens composition in the packaging container 8 are contacted. 7 is covered with, for example, an aluminum film and sealed.

Then, a contact lens package using the contact lens composition of the present invention is manufactured by performing sterilization by an autoclave or the like.

The contact lens molding method is not limited to the method (molding) using the female mold 2 and the male mold 3 described above, and other molding methods such as lace cutting and spin casting are used. Can be adopted.

In addition, a contact lens (cured lens, non-hydrated lens) molded by the same method as described above is directly immersed in the contact lens composition of the present application, and then sealed and autoclaved (autoclave, etc.) May be used to produce a contact lens package using the contact lens composition of the present invention.

The cured lens is pre-hydrated with a solution different from the contact lens composition of the present application (for example, an aqueous solution containing a surfactant) or the contact lens composition of the present application, and then the hydrated lens. The contact lens package using the composition for contact lenses of the present invention may be produced by immersing the composition in the composition for contact lenses of the present application and then performing sealing and sterilization treatment in the same manner.

Although it is conceivable to use vinyl acetate monomer and vinyl pyrrolidone monomer as a raw material for the contact lens, only polymerizing N-vinyl pyrrolidone does not provide a sufficient protein adsorption inhibiting effect. Due to the high hydrophobicity, vinyl acetate and other hydrophilic monomers are not mixed uniformly, so that a uniform polymer cannot be obtained, resulting in a uniform and smooth surface and a feeling of wearing There arises a disadvantage that an excellent contact lens cannot be obtained. Further, there arises a disadvantage that excellent optical characteristics required as performance required for the vision correction device cannot be obtained.

That is, the present invention in which a copolymer having a ratio of vinyl acetate and vinyl pyrrolidone that is optimal for inhibiting protein adsorption to the contact lens is polymerized after polymerizing the contact lens raw material is advantageous from the viewpoint of inhibiting protein adsorption. It can be said that.

It is also conceivable to coat the surface of the contact lens with a vinyl acetate-vinyl pyrrolidone copolymer by graft polymerization or the like. However, in such a surface coating, a group that is present inside the contact lens and is likely to adsorb proteins is used. Since it cannot coat | cover, the protein adsorption | suction suppression effect is limited only to the contact lens surface with a coating layer, and the problem that sufficient protein adsorption | suction suppression effect is not acquired arises.

That is, it can be said that the present invention in which a vinyl acetate-vinylpyrrolidone copolymer having an appropriate molecular weight that can penetrate into the inside of a contact lens is adsorbed is more advantageous from the viewpoint of suppressing protein adsorption.

Further, the contact lens composition of the present invention can be used as the above-mentioned packaging solution, as well as eye drops for contact lenses, eye wash agents for contact lenses, contact lens mounting solutions, contact lens care agents (for example, storage for contact lenses) Liquid, contact lens disinfectant, contact lens cleaning agent, contact lens cleaning preservative) and the like.

The contact lens composition of the present invention is not used as a lens care solution such as a contact lens disinfectant or a contact lens cleaning agent containing a singlet oxygen generating reagent.

The contact lens composition of the present invention can also be used in the form of a hydration solution for hydrating a polymerized and molded contact lens (cured lens) in the above contact lens manufacturing process.

That is, the “packaging solution” which is an example of the usage form of the composition for contact lenses of the present invention is the one immediately after polymerization, molding, or immediately after hydrating the molded lens in the contact lens manufacturing process. This is a solution for immersing contact lenses (ie, unused lenses) (and then sterilizing, such as autoclaving if necessary), and is used only for the care of already used contact lenses. There is no lens cleaning / disinfecting preservative (multi-purpose solution: MPS) or a step of immersing the contact lens in the composition. is there.

Further, when the contact lens composition of the present invention is used as the packaging liquid, the volume of the contact lens composition used per one contact lens package is usually 0.01 to 10 ml. Among these, 0.1 to 5 ml is preferable, and 0.4 to 2 ml is more preferable.

Furthermore, when the contact lens composition of the present invention is used as the packaging liquid, the contact lens package is manufactured by sterilization such as high-pressure steam sterilization after sealing. The composition preferably contains 0.00005% or less of a preservative or is not compounded, more preferably contains 0.00001% or less or is not compounded, and particularly preferably is no compound. This is because the preservative may be adsorbed to the contact lens when the contact lens is immersed for a long period of time, such as a packaging solution. Examples of preservatives include polydronium chloride, alkyldiaminoethyl glycine hydrochloride, sodium benzoate, benzalkonium chloride, benzethonium chloride, chlorhexidine gluconate, chlorobutanol, methyl paraoxybenzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate, Examples include butyl paraoxybenzoate, oxyquinoline sulfate, and biguanide compounds (specifically, polyhexamethylene biguanide or its hydrochloride).

In the present invention described above, the following effects can be obtained.

(1) Since the contact lens composition of the present invention contains a vinyl acetate-vinylpyrrolidone copolymer, the contact lens composition of the present invention is packaged in a packaging container together with the contact lens. By using it as a solution, it is possible to enhance the protein adsorption suppression effect on the contact lens without performing a complicated treatment.

(2) In particular, even when proteins and lipids coexist like tears, it is possible to enhance the protein adsorption suppression effect on the contact lens.

(3) In addition, since it has a vinyl acetate-vinyl pyrrolidone copolymer with a vinyl acetate / vinyl pyrrolidone ratio of 80/20 to 20/80, it is possible to improve solubility in water and ethanol. become.

(4) In addition, by adjusting the concentration of the vinyl acetate-vinylpyrrolidone copolymer in the contact lens composition to 0.0001 to 10 (w / v)%, protein adsorption can be suppressed without increasing costs. The effect can be surely exhibited.

(5) Since the vinyl acetate-vinyl pyrrolidone copolymer has a weight average molecular weight of 5000 to 500,000, the vinyl acetate-vinyl pyrrolidone copolymer can easily enter the matrix of the contact lens material, and the protein It becomes possible to coat groups that are easily adsorbed.

(6) Further, in the contact lens composition of the present invention, the above-mentioned vinyl acetate-vinyl pyrrolidone copolymer suppresses protein adsorption to the contact lens, thereby reducing the dryness of the eye and moisturizing feeling. It becomes possible to improve.

(7) Further, in the contact lens composition of the present invention, the above-mentioned vinyl acetate-vinyl pyrrolidone copolymer suppresses friction on the keratoconjunctival surface of the contact lens, thereby improving the wearing feeling of the contact lens. be able to.

(8) Further, since the composition for contact lenses of the present invention contains a terpenoid, it can give a refreshing feeling after wearing the contact lens, and the dryness of the eyes is further reduced and moistened. The feeling can be improved. Further, it is possible to suppress upper and lower eyelids caused by blinking and frictional resistance with the keratoconjunctiva. Furthermore, it is possible to suppress the feeling of dryness due to the contact lens wearing itself, to improve the feeling of moisture, and to suppress the feeling of foreign matter.

(9) Further, the contact lens composition of the present invention can particularly suppress the adsorption of proteins to the soft contact lens.

(10) In addition, since the composition for contact lenses of the present invention contains a vinyl acetate-vinylpyrrolidone copolymer and a terpenoid, the expression level of mucin is dramatically increased and the dryness of the eye is dramatically increased. Can be reduced.

(11) Since the contact lens composition of the present invention contains a vinyl acetate-vinylpyrrolidone copolymer, the contact lens composition of the present invention is enclosed in a packaging container together with the contact lens. By using it as a packaging solution, it becomes possible to enhance the lipid adsorption suppression effect on the contact lens without performing a complicated treatment. This effect is particularly prominent when the contact lens is a silicone hydrogel lens.

In addition, polyvinyl caprolactam represented by the following formula (2) may be used instead of the above-mentioned vinyl acetate-vinyl pyrrolidone copolymer.

(In the formula, n is an integer of 400 to 700.)

By using such a polyvinyl caprolactam, it is possible to enhance the protein adsorption suppressing effect on the contact lens without performing a complicated treatment as in the case of the vinyl acetate-vinyl pyrrolidone copolymer described above.

In addition, as described above, the method for producing a contact lens of the present invention includes a step of contacting a contact lens with a composition for contact lens containing a vinyl acetate-vinyl pyrrolidone copolymer.

In addition, as described above, the method for producing a contact lens of the present invention includes a step of bringing a contact lens composition containing a vinyl acetate-vinylpyrrolidone copolymer into contact with the contact lens, and the contact lens composition and the contact lens. And a method for manufacturing a packaged contact lens.

Furthermore, the present application is manufactured by a method comprising a step of contacting a contact lens with a composition for contact lenses containing a vinyl acetate-vinyl pyrrolidone copolymer, and a step of sealing the contact lens composition and the contact lens. In addition, contact lens packages (contact lens products) are included.

Hereinafter, the present invention will be described based on examples. In addition, this invention is not limited to these Examples, These Examples can be changed and changed based on the meaning of this invention, and they are not excluded from the scope of the invention. Absent.

[Test 1 Protein adsorption test]
Example 1-1
(Preparation of contact lens composition and preparation of test contact lens)
In 100 g of sterilized purified water, 2 g (concentration: 1 (w / v)%) of vinyl acetate-vinylpyrrolidone copolymer (manufactured by Osaka Organic Chemical Industry Co., Ltd., trade name: Acorn M, molecular weight of about 70000), buffering agent Sodium hydrogen phosphate dodecahydrate (Wako Pure Chemical Industries, Ltd.) 0.5993 g (concentration: 0.5993 (w / v)%), sodium dihydrogen phosphate dihydrate (Wako Pure Chemical ( Ltd.) 0.0528 g (concentration: 0.0528 (w / v)%) and sodium chloride as an isotonic agent (manufactured by Wako Pure Chemical Industries, Ltd.) 0.83 g (concentration: 0.83 (w / V)%) was added and dissolved to prepare a composition for contact lenses. The prepared contact lens composition had a pH of 7.4.

Next, a commercially available Omafilcon A lens (manufactured by Cooper Vision, trade name: Pro Clear One Day) was prepared. Next, this contact lens is taken out from the packaging container, and the taken out contact lens is a phosphate buffer-containing physiological saline (sodium chloride concentration: 0.83 (w / v)%, sodium hydrogenphosphate dodecahydrate concentration: 0.5993 (w / v)%, sodium dihydrogen phosphate dihydrate concentration: 0.0528 (w / v)%), and then immersed in a sufficient amount of phosphate buffered saline. , Left overnight.

Next, the prepared contact lens composition (4 ml) was placed in a PFA (tetrafluoroethylene-perfluoroalkyl vinyl ether copolymer) container. After removing the contact lens from the phosphate buffer-containing physiological saline, the contact lens was rinsed with a phosphate buffer-containing physiological saline, and then the moisture of the contact lens was removed using a lint-free nonwoven fabric.

Next, the contact lens is immersed in the contact lens composition to bring the contact lens into contact with the contact lens composition, and the contact lens and the contact lens composition are sealed and autoclaved (121 ° C., 20 Minutes) and left at room temperature for 120 hours to produce a test contact lens.

(Protein adsorption test)
Next, buffer solution (sodium chloride concentration: 0.9 (w / v)%, sodium dihydrogen phosphate dodecahydrate concentration: 0.045 (w / v)%, calcium chloride dihydrate concentration: 0 Add lysozyme chloride derived from egg white to 0.3 (w / v)% to 0.15 (w / v)%, adjusted to pH 7 using 1M sodium hydroxide solution) In addition, oleic acid as a lipid is 0.003 (w / v)%, linoleic acid is 0.003 (w / v)%, tripalmitin is 0.0405 (w / v)%, and cetanol is 0.01. (W / v)%, palmitic acid 0.003 (w / v)%, spalm aceti 0.0405 (w / v)%, cholesterol 0.004 (w / v)%, and palmitic acid cholesterol 0.0. 004 (w / v)% and lecithin egg origin 0.141 (W / v) was added to a%, to prepare a lysozyme solution containing lipids.

Next, after the prepared lysozyme solution was filtered, 2 ml was poured into a vial (glass, capacity: 10 ml).

Next, the contact lens is taken out from the contact lens composition, washed with the phosphate buffer-containing physiological saline twice, and then the moisture of the contact lens is removed using a lint-free nonwoven fabric. Removed.

Next, the contact lens was immersed in a lysozyme solution, and the contact lens was vibrated (120 times / min) at 34 ° C. for 7 hours using a shaker to adsorb the protein to the contact lens.

Next, the contact lens was taken out from the lysozyme solution, washed with the phosphate buffer-containing physiological saline twice, and the contact lens was dehydrated with a lint-free nonwoven fabric.

Next, the contact lens was poured into a new vial (glass, volume: 10 ml) for protein extraction (sodium dodecyl sulfate concentration: 1 (w / v)%, sodium carbonate concentration: 1 (w / v )%) Soaked in 2 ml.

Next, the protein adsorbed on the contact lens was extracted by vibrating the contact lens (120 times / min) at 34 ° C. for 14 hours using a shaker.

Next, using the reagent for protein concentration measurement (Thermo Scientific Co., Ltd., trade name: Micro BCA Protein Assay Kit), the protein in the solution for protein extraction was quantified, and the obtained value From this, the amount of protein adsorbed on one contact lens was calculated. The results are shown in Table 1.

Example 1-2
Except for using 2 g (concentration: 1 (w / v)%) of vinyl acetate-vinylpyrrolidone copolymer (trade name: PVA-6450, molecular weight of about 70000, manufactured by Osaka Organic Chemical Industry Co., Ltd.) A contact lens composition was prepared in the same manner as in Example 1-1, and a test contact lens was further prepared. Thereafter, a protein adsorption test was performed in the same manner as in Example 1-1. The results are shown in Table 1.

(Example 1-3)
Instead of the above-mentioned vinyl acetate-vinyl pyrrolidone copolymer, 2.5 g (concentration: 1 (w / v)) of polyvinyl caprolactam (manufactured by BASF Japan Ltd., trade name: Rubiscol Plus, molecular weight: 70000-80000) %) Except that it was used, a contact lens composition was prepared in the same manner as in Example 1-1 above, and a test contact lens was further prepared. Thereafter, a protein adsorption test was performed in the same manner as in Example 1-1. The results are shown in Table 1.

(Example 1-4)
First, a test contact lens was produced in the same manner as in Example 1-1 described above. Thereafter, a protein adsorption test was conducted in the same manner as in Example 1-1 except that the lysozyme solution containing no lipid was used as the lysozyme solution. The results are shown in Table 2.

(Example 1-5)
First, a test contact lens was produced in the same manner as in Example 1-2 described above. Thereafter, a protein adsorption test was performed in the same manner as in Example 1-2 except that the lysozyme solution containing no lipid was used as the lysozyme solution. The results are shown in Table 2.

(Example 1-6)
First, a contact lens composition was prepared in the same manner as in Example 1-1 described above. Thereafter, as a commercially available contact lens, a test piece was used in the same manner as in Example 1-1 except that an etafilcon A lens (manufactured by Johnson & Johnson, trade name: 2 week Accuview) was used. A contact lens was prepared, and a protein adsorption test was performed in the same manner as in Example 1-1. The above results are shown in Table 3.

(Example 1-7)
First, a contact lens composition was prepared in the same manner as in Example 1-2 described above. Thereafter, as a commercially available contact lens, an Etafilcon A lens (manufactured by Johnson & Johnson, trade name: 2 week Accuview) was used to produce a test contact lens. Thereafter, a protein adsorption test was performed in the same manner as in Example 1-1. The above results are shown in Table 3.

(Example 1-8)
First, a contact lens composition was prepared in the same manner as in Example 1-1 described above. Then, as a commercially available contact lens, an etafilcon A lens (manufactured by Johnson & Johnson, trade name: 2 week Accuview) was used to prepare a test contact lens, and the lysozyme solution containing no lipid as described above was used as a lysozyme solution. A protein adsorption test was performed in the same manner as in Example 1-1 except that the solution was used. The results are shown in Table 4.

(Example 1-9)
First, a contact lens composition was prepared in the same manner as in Example 1-2 described above. Then, as a commercially available contact lens, an etafilcon A lens (manufactured by Johnson & Johnson, trade name: 2 week Accuview) was used to prepare a test contact lens, and the lysozyme solution containing no lipid as described above was used as a lysozyme solution. A protein adsorption test was performed in the same manner as in Example 1-1 except that the solution was used. The results are shown in Table 4.

(Comparative Example 1-1)
A test contact lens was prepared using the above-described phosphate buffer-containing physiological saline containing no vinyl acetate-vinyl pyrrolidone copolymer instead of the prepared contact lens composition, and the above-mentioned Examples. A protein adsorption test was performed in the same manner as in 1-1. The results are shown in Table 1.

(Comparative Example 1-2)
In place of the prepared contact lens composition, a test contact lens was prepared using the above-described phosphate buffer-containing physiological saline not containing a vinyl acetate-vinyl pyrrolidone copolymer, and a lysozyme solution was used. Using the lysozyme solution containing no lipid, the protein adsorption test was performed in the same manner as in Example 1-1. The results are shown in Table 2.

(Comparative Example 1-3)
Instead of the prepared contact lens composition, the above-mentioned phosphate buffer-containing physiological saline containing no vinyl acetate-vinyl pyrrolidone copolymer is used, and as a commercially available contact lens, etafilcon A (etafilcon A) is used. A) A contact lens for test was prepared using a lens (trade name: 2 week Accuview manufactured by Johnson & Johnson), and a protein adsorption test was performed in the same manner as in Example 1-1. The above results are shown in Table 3.

(Comparative Example 1-4)
A test contact lens was prepared using the above-described phosphate buffer-containing physiological saline containing no vinyl acetate-vinyl pyrrolidone copolymer instead of the prepared contact lens composition. As the lens, an etafilcon A lens (manufactured by Johnson & Johnson, trade name: 2 week Accuview) is used, and the above lysozyme solution not containing lipid is used as the lysozyme solution. A protein adsorption test was performed in the same manner as in 1-1. The results are shown in Table 4.

As shown in Table 1, any of the contact lens compositions of Examples 1-1 to 1-3 was compared with Comparative Example 1-1 containing no vinyl acetate-vinyl pyrrolidone copolymer or polyvinyl caprolactam. It can be seen that adsorption of about 30 to 80% of protein can be suppressed.

Further, as shown in Table 2, any of the contact lens compositions of Examples 1-4 to 1-5 was compared with Comparative Example 1-2 not containing a vinyl acetate-vinylpyrrolidone copolymer. It can be seen that about 20% of protein adsorption can be suppressed.

Further, as shown in Table 3, any of the contact lens compositions of Examples 1-6 to 1-7 was compared with Comparative Example 1-3 containing no vinyl acetate-vinyl pyrrolidone copolymer. It can be seen that about 80% of protein adsorption can be suppressed.

Further, as shown in Table 4, any of the contact lens compositions of Examples 1-8 to 1-9 was compared with Comparative Example 1-4 not containing a vinyl acetate-vinylpyrrolidone copolymer. It can be seen that about 10 to 20% of protein adsorption can be suppressed.

Further, from Examples 1-1 to 1-9, the composition for contact lenses of the present invention is a soft contact lens classified as Group II in the soft contact lens classification according to FDA standards (Ofilfilcon A). It can be seen that an excellent protein adsorption inhibitory effect can be exhibited for both the lens) and the soft contact lens (Etafilcon A lens) classified into Group IV.

In particular, as can be seen from Examples 1-6 to 1-7, the composition for contact lenses of the present invention is an excellent protein for soft contact lenses (Etafilcon A lens) lenses classified as Group IV. It can be seen that the adsorption suppressing effect can be exhibited.

This is because in soft contact lenses classified into Group IV, protein enters the contact lens because the gap inside the contact lens is large, but in the contact lens composition of the present invention, Because it contains a vinyl acetate-vinyl pyrrolidone copolymer having an appropriate molecular weight that can penetrate into the surface of the contact lens, an excellent protein adsorption suppression effect was exhibited not only on the contact lens surface but also inside the contact lens. Conceivable.

Furthermore, from Examples 1-1 to 1-3 and 1-6 to 1-7, the composition for contact lenses of the present invention has an effect of inhibiting protein adsorption on contact lenses, particularly when proteins and lipids coexist. It can be seen that can be increased.

This is because in Examples 1-1 to 1-3 and 1-6 to 1-7, a vinyl acetate-vinylpyrrolidone copolymer (or polyvinylcaprylactam) is contained, so that a contact lens is formed. A charged group (for example, quaternary ammonium group, phosphoric acid group, carboxyl group) and a hydrophobic group (for example, siloxane group) in the material may be combined with an uncharged vinyl acetate-vinylpyrrolidone copolymer (or polyvinyl capri This is considered to be because the adsorption of protein on the surface of the contact lens was suppressed.

(Example 1-10)
Using 0.2 g (concentration: 0.1 (w / v)%) of a vinyl acetate-vinylpyrrolidone copolymer (trade name: Acorn M, molecular weight of about 70,000, manufactured by Osaka Organic Chemical Industry Co., Ltd.), surface activity A contact lens composition was prepared in the same manner as in Example 1-1 except that polysorbate 80 (0.1 g, concentration: 0.1 (w / v)%), an agent, was further added. did. Thereafter, as a commercially available contact lens, an etafilcon A lens (manufactured by Johnson & Johnson, trade name: One Day Accuview) was used, and a test contact was conducted in the same manner as in Example 1-1 except that autoclaving was not performed. A lens was produced. Thereafter, a protein adsorption test was performed in the same manner as in Example 1-1. The results are shown in Table 5.

(Example 1-11)
Using 0.02 g (concentration: 0.01 (w / v)%) of a vinyl acetate-vinylpyrrolidone copolymer (trade name: Acorn M, molecular weight of about 70,000, manufactured by Osaka Organic Chemical Industry Co., Ltd.), surface activity A contact lens composition was prepared in the same manner as in Example 1-1 except that polysorbate 80 (0.1 g, concentration: 0.1 (w / v)%), an agent, was further added. did. Thereafter, an etafilcon A lens (manufactured by Johnson & Johnson, trade name: One-Day Accuview) was used as a commercially available contact lens, and the autoclave treatment was not performed, and the room temperature storage time was set to 48 hours. Test contact lenses were prepared in the same manner as in 1. Thereafter, a protein adsorption test was performed in the same manner as in Example 1-1. The results are shown in Table 5.

(Example 1-12)
Vinyl acetate-vinylpyrrolidone copolymer (manufactured by BASF Japan Ltd., trade name: Luviskol (registered trademark) VA64P, VP / VA ratio: 60/40, molecular weight 50000-60000) 0.01 g (concentration: 0.01 ( w / v)%), and the surfactant polysorbate 80 (0.1 g, concentration: 0.1 (w / v)%) was further included, as described in Example 1-1. A contact lens composition was prepared in the same manner as described above. Thereafter, an etafilcon A lens (manufactured by Johnson & Johnson, trade name: One-Day Accuview) was used as a commercially available contact lens, and the autoclave treatment was not performed, and the room temperature storage time was set to 48 hours. Test contact lenses were prepared in the same manner as in 1. Thereafter, a protein adsorption test was performed in the same manner as in Example 1-1. The results are shown in Table 5.

(Example 1-13)
Vinyl acetate-vinylpyrrolidone copolymer (manufactured by BASF Japan Ltd., trade name: Luviskol (registered trademark) VA73E, VP / VA ratio: 70/30, molecular weight 40000-60000) 0.02 g (concentration: 0.01 ( w / v)%), and the surfactant polysorbate 80 (0.1 g, concentration: 0.1 (w / v)%) was further included, as described in Example 1-1. A contact lens composition was prepared in the same manner as described above. Thereafter, an etafilcon A lens (manufactured by Johnson & Johnson, trade name: One-Day Accuview) was used as a commercially available contact lens, and the autoclave treatment was not performed, and the room temperature storage time was set to 48 hours. Test contact lenses were prepared in the same manner as in 1. Thereafter, a protein adsorption test was performed in the same manner as in Example 1-1. The results are shown in Table 5.

(Comparative Example 1-5)
Instead of the prepared contact lens composition, it contains no polyacetate 80 (0.1 g, concentration: 0.1 (w / v)%) as a surfactant without containing vinyl acetate-vinyl pyrrolidone copolymer. The above-mentioned physiological saline containing a phosphate buffer was used, and an etafilcon A lens (manufactured by Johnson & Johnson, trade name: One-Day Accuview) was used as a commercially available contact lens. A test contact lens was produced in the same manner as in Example 1-1 except that the storage time was 48 hours. Thereafter, a protein adsorption test was performed in the same manner as in Example 1-1. The results are shown in Table 5.

As shown in Table 5, even when the concentration of the vinyl acetate-vinyl pyrrolidone copolymer is 0.1 or 0.01 (w / v)%, the vinyl acetate-vinyl pyrrolidone copolymer is contained. It can be seen that about 20 to 60% of protein adsorption can be suppressed as compared with Comparative Example 1-5, which is not present.

Even when the vinyl acetate / vinyl pyrrolidone copolymer has a different ratio (mass ratio) of vinyl acetate / vinyl pyrrolidone, it is different from that of Comparative Example 1-5 containing no vinyl acetate-vinyl pyrrolidone copolymer. It can be seen that adsorption of about 15 to 20% of protein can be suppressed.

(Example 1-14)
Using 0.2 g (concentration 0.1 (w / v)%, molecular weight about 70000) of a vinyl acetate-vinylpyrrolidone copolymer (trade name: Acorn M, manufactured by Osaka Organic Chemical Industry Co., Ltd.), a surfactant A contact lens composition was prepared in the same manner as in Example 1-1 except that polysorbate 80 (0.1 g, concentration: 0.1 (w / v)%) was further added. A test contact lens was produced in the same manner as in Example 1-1 except that the autoclave treatment was not performed and the room temperature storage time was 48 hours. Thereafter, a protein adsorption test was performed in the same manner as in Example 1-1. The results are shown in Table 6.

(Example 1-15)
Using 0.02 g (concentration 0.01 (w / v)%) of a vinyl acetate-vinylpyrrolidone copolymer (Osaka Organic Chemical Co., Ltd., trade name: Acorn M, molecular weight of about 70,000) A contact lens composition was prepared in the same manner as in Example 1-1 except that polysorbate 80 (0.1 g, concentration: 0.1 (w / v)%) was further added. A test contact lens was produced in the same manner as in Example 1-1 except that the autoclave treatment was not performed and the room temperature storage time was 48 hours. Thereafter, a protein adsorption test was performed in the same manner as in Example 1-1. The results are shown in Table 6.

(Comparative Example 1-6)
Instead of the prepared contact lens composition, a surfactant polysorbate 80 (0.1 g, concentration) was added to the above-mentioned phosphate buffer-containing physiological saline that does not contain a vinyl acetate-vinylpyrrolidone copolymer. : 0.1 (w / v)%), a test contact lens was prepared in the same manner as in Example 1-1 except that the autoclave treatment was not performed and the room temperature storage time was 48 hours. It was created. Thereafter, a protein adsorption test was performed in the same manner as in Example 1-1. The results are shown in Table 6.

As shown in Table 6, even when the concentration of the vinyl acetate-vinyl pyrrolidone copolymer was 0.1 or 0.01%, Comparative Example 1 containing no vinyl acetate-vinyl pyrrolidone copolymer It can be seen that about 10% of protein adsorption can be suppressed as compared to 6.

[Test 2 Lipid adsorption test]
Example 2-1
(Preparation of contact lens composition and preparation of test contact lens)
To 100 g of sterilized purified water, 1 g of vinyl acetate-vinylpyrrolidone copolymer (manufactured by Osaka Organic Chemical Industry Co., Ltd., trade name: Acorn M, molecular weight of about 70000) (concentration: 0.5 (w / v)%), Polysorbate 80 as a surfactant (0.1 g, concentration: 0.1 (w / v)%), sodium hydrogenphosphate 12 hydrate as a buffer (manufactured by Wako Pure Chemical Industries, Ltd.) 0.5993 g ( Concentration: 0.5993 (w / v)%), sodium dihydrogen phosphate dihydrate (manufactured by Wako Pure Chemical Industries, Ltd.) 0.0528 g (concentration: 0.0528 (w / v)%), and the like Sodium chloride as a tonicity agent (manufactured by Wako Pure Chemical Industries, Ltd.) 0.83 g (concentration: 0.83 (w / v)%) was added and dissolved to prepare a composition for contact lenses. The prepared contact lens composition had a pH of 7.4.

Next, a commercially available Senofilcon A lens (manufactured by Johnson & Johnson, trade name: Accuview Oasis), which is a silicone hydrogel lens, is taken out from the packaging container, and the taken out contact lens is filled with the above-mentioned phosphate buffer-containing physiological saline. After washing with water, it was immersed in a sufficient amount of physiological saline containing a phosphate buffer and left overnight. Next, a contact lens for test was prepared by immersing in a 4 ml contact lens composition per lens in a PFA (tetrafluoroethylene-perfluoroalkyl vinyl ether copolymer) container and leaving it at room temperature for 72 hours. .

(Lipid adsorption test)
First, a lipid suspension was prepared. More specifically, 0.06 g of oleic acid, 0.06 g of linoleic acid, 0.81 g of tripalmitin, 0.2 g of cetanol, 0.06 g of palmitic acid, 0.81 g of palm acetylate, 0.08 g of cholesterol, 0. 08 g and 2.83 g derived from lecithin egg were weighed and mixed, and dissolved by heating at about 70 ° C.

Next, phosphate / borate buffer (sodium chloride 0.9 (w / v)%, potassium dihydrogen phosphate 0.5 (w / v)%, borax 1.19 (w / v)%) 5 g of a lipid mixture component in a heated and dissolved state and 1 L of a phosphate / borate buffer solution were stirred with a homodisper (70 ° C., 5000 rpm, 10 minutes), filtered, and further phosphoric acid. What was adjusted to pH 7.0 was used as a lipid suspension.

2 ml of this lipid suspension is placed in a glass vial (capacity: 10 ml), and the test contact lens is rinsed with a sufficient amount of physiological saline containing a phosphate buffer, immersed in it, and shaken at 37 ° C. for 16 hours. I let you.

Next, the lens was taken out, rinsed with about 100 ml of phosphate buffered saline, placed in the bottom of a 2 ml Eppendorf tube, and dried overnight at room temperature in a vacuum dryer (15 mmHg).

Next, the dried lens was placed in 1 ml of a lipid extract (ethanol: ether = 3: 1) and immersed for 10 minutes or longer to extract the lipid adsorbed on the lens. 0.5 ml of the lipid extract was taken, put into a new 15 ml centrifuge tube (manufactured by PP), and the solvent was removed with nitrogen gas while heating at about 70 ° C.

Next, 0.05 ml of absolute ethanol and 2.5 ml of concentrated sulfuric acid were added to the residue and treated in a 90 ° C. hot water bath for 30 minutes.

After standing to cool to room temperature, 0.4 ml was collected, transferred to a new centrifuge tube (PP), and 6 ml of vanillin solution (0.6 (w / v)% vanillin aqueous solution: phosphoric acid = 1: 4) was added. In addition, the sample was treated in a 37 ° C. water bath for 15 minutes under light shielding, 200 μl of each sample was applied to a 96-well multiplate, and the absorbance at 540 nm was measured with a spectrophotometer.

The 0.6 (w / v)% vanillin aqueous solution is obtained by dissolving 0.6 g of vanillin with 8 ml of absolute ethanol and making up to 100 ml with distilled water.

Next, the amount of lipid adsorbed on the contact lens was determined using a calibration curve prepared using olive oil as an indicator substance in the same procedure. The results are shown in Table 7.

(Example 2-2)
Except for using 0.2 g (concentration: 0.1 (w / v)%) of vinyl acetate-vinylpyrrolidone copolymer (manufactured by Osaka Organic Chemical Industry Co., Ltd., trade name: Acorn M, molecular weight of about 70000). A test contact lens was manufactured in the same manner as in Example 2-1 described above. Thereafter, a lipid adsorption test was conducted in the same manner as in Example 2-1. The results are shown in Table 7.

(Example 2-3)
0.1 g (concentration: 0.005%) of vinyl acetate-vinylpyrrolidone copolymer (manufactured by BASF Japan Ltd., trade name: Luviskol (registered trademark) VA64P, VP / VA ratio: 60/40, molecular weight of about 50000-60000). 1 (w / v)%) A test contact lens was produced in the same manner as in Example 2-1 described above except that 1 (w / v)% was used. Thereafter, a lipid adsorption test was conducted in the same manner as in Example 2-1. The results are shown in Table 7.

(Example 2-4)
1 g (concentration: 0.5 (w / w), vinyl acetate-vinyl pyrrolidone copolymer (manufactured by BASF Japan Ltd., trade name: Luviskol (registered trademark) VA73E, VP / VA ratio: 70/30, molecular weight 40000-60000)) A test contact lens was produced in the same manner as in Example 2-1 except that v)%) was used. Thereafter, a lipid adsorption test was conducted in the same manner as in Example 2-1. The results are shown in Table 7.

(Example 2-5)
0.2 g (concentration: 0.1) of vinyl acetate-vinylpyrrolidone copolymer (manufactured by BASF Japan Ltd., trade name: Luviskol (registered trademark) VA73E, VP / VA ratio: 70/30, molecular weight 40000-60000) (W / v)%) A test contact lens was produced in the same manner as in Example 2-1 except that it was used. Thereafter, a lipid adsorption test was conducted in the same manner as in Example 2-1. The results are shown in Table 7.

(Comparative Example 2-1)
In place of the prepared contact lens composition, a test contact lens was prepared in the same manner as in Example 2-1 using a composition not containing the above-mentioned vinyl acetate-vinyl pyrrolidone copolymer. did. Thereafter, a lipid adsorption test was conducted in the same manner as in Example 2-1. The results are shown in Table 7.

As shown in Table 7, in any of the contact lens compositions of Examples 2-1 to 2-5, as compared with Comparative Example 2-1, which did not contain a vinyl acetate-vinylpyrrolidone copolymer, It can be seen that the adsorption of 10-30% lipid can be suppressed.

In addition, it can be seen that any of the contact lens compositions of Examples 2-1 to 2-5 can exhibit an extremely excellent lipid adsorption inhibitory effect on a silicone hydrogel lens to which lipids particularly easily adhere. .

[Test 3 Friction test]
Example 3-1
(Preparation of contact lens composition and preparation of test contact lens)
To 100 g of sterilized purified water, 0.2 g (concentration: 0.1 (w / v)%) of vinyl acetate-vinylpyrrolidone copolymer (manufactured by Osaka Organic Chemical Industry Co., Ltd., trade name: Acorn M, molecular weight of about 70,000) ), Polysorbate 80 as a surfactant (0.1 g, concentration: 0.1 (w / v)%), sodium hydrogen phosphate 12 hydrate as a buffer (manufactured by Wako Pure Chemical Industries, Ltd.) 5993 g (concentration: 0.5993 (w / v)%), sodium dihydrogen phosphate dihydrate (manufactured by Wako Pure Chemical Industries, Ltd.) 0.0528 g (concentration: 0.0528 (w / v)%), And 0.88 g (concentration: 0.83 (w / v)%) of sodium chloride (made by Wako Pure Chemical Industries, Ltd.), which is an isotonic agent, was added and dissolved to prepare a composition for contact lenses. . The prepared contact lens composition had a pH of 7.4.

Next, using a commercially available omafilcon A lens (manufactured by Cooper Vision Co., Ltd., trade name: Pro Clear One Day), the same treatment as in Example 1-1 was carried out except that the autoclave treatment was not performed. A contact lens was prepared.

(Friction test)
Next, the dynamic friction coefficient of the test contact lens was measured using a tribomaster (manufactured by Trinity Lab Co., Ltd., trade name: TL201S) which is a static friction measuring machine.

Specifically, the contact lens to be tested was fixed to a contactor, artificial leather was attached to a moving table, and about 15 ml of physiological saline (manufactured by Otsuka Pharmaceutical Factory Co., Ltd.) was dropped thereon. Then, a contact having a contact lens fixed thereon is fixed, and the friction tester is moved at a speed of 2.0 mm / sec with a load of 50 g applied, and the dynamic friction coefficient 10 seconds after the start of the movement. Was measured. An R contact was used as the contact.

Then, the measured data was transferred to a computer using a Condition catcher Model (manufactured by Kyushu Kyodo Co., Ltd., trade name: MPL-10A-128), and the average value of the dynamic friction coefficients was obtained. The above results are shown in Table 8 (N = 3).

The average value of the dynamic friction coefficient indicates the degree of friction on the keratoconjunctival surface of the contact lens, and the higher the friction, the worse the wearing feeling.

(Comparative Example 3-1)
A test contact lens was prepared in the same manner as in Example 3-1 above, using a composition not containing the above-mentioned vinyl acetate-vinylpyrrolidone copolymer instead of the prepared contact lens composition. did. Thereafter, a friction test was performed in the same manner as in the above-described 3-1. Table 8 shows the above results.

(Example 3-2)
A contact lens composition was produced in the same manner as in Example 3-1. Then, as a commercially available contact lens, a test contact lens was prepared using a Balafilcon A lens (trade name: Medalist Fresh Fit, manufactured by Bosch Lomm), and the above Example 3-1 was used. Similarly, a friction test was performed. The above results are shown in Table 9.

(Comparative Example 3-2)
Instead of the prepared contact lens composition, a composition not containing the above-mentioned vinyl acetate-vinyl pyrrolidone copolymer was used, and as a commercially available contact lens, a Balafilcon A lens (manufactured by Bosch Lom) A test contact lens was produced in the same manner as in Example 3-1, except that (trade name: Medalist Fresh Fit) was used. Thereafter, a friction test was conducted in the same manner as in the above-described 3-1. The above results are shown in Table 9.

(Example 3-3)
A contact lens composition was produced in the same manner as in Example 3-1. Subsequently, Example 3-1, except that a test contact lens was produced using a Lotrafilcon B lens (manufactured by Ciba Vision, trade name: Air Optics Aqua) as a commercially available contact lens. Similarly, a friction test was performed. Table 10 shows the above results.

(Comparative Example 3-3)
A composition not containing the above-mentioned vinyl acetate-vinylpyrrolidone copolymer is used in place of the prepared contact lens composition, and a lotafilcon B lens (manufactured by Ciba Vision) is used as a commercially available contact lens. A test contact lens was manufactured in the same manner as in Example 3-1, except that a test contact lens was manufactured using a product name: Air Optics Aqua. Thereafter, a friction test was performed in the same manner as in the above-described 3-1. Table 10 shows the above results.

As shown in Tables 8 to 10, when applied to any of the contact lenses of Examples 3-1 to 3-3, the vinyl acetate-vinyl pyrrolidone copolymer was contained. It can be seen that about 15 to 35% of friction can be suppressed as compared with Comparative Examples 3-1 to 3-3 not containing a vinylpyrrolidone copolymer.

In particular, as can be seen from Example 3-1, the composition for contact lenses of the present invention exhibits an extremely excellent friction suppressing effect on soft contact lenses (Omafilcon A lenses) lenses classified as Group II. I know that

[Test 4: Evaluation of feeling when worn with humans and friction test of lenses after human wearing]
Example 4
(Preparation of contact lens composition and preparation of test contact lens)
In 100 g of sterilized purified water, 0.02 g (concentration: 0.01 (w / v)%) of vinyl acetate-vinylpyrrolidone copolymer (manufactured by Osaka Organic Chemical Industry Co., Ltd., trade name: Acorn M, molecular weight of about 70,000) ), L-menthol as a cooling agent, 0.002 g (concentration: 0.002 (w / v)%), polyoxyl stearate 40 as a surfactant (0.1 g, concentration: 0.1 (w / v) )%) And Pluronic P123 (0.1 g, 0.1 (w / v)%), sodium hydrogen phosphate dodecahydrate (manufactured by Wako Pure Chemical Industries, Ltd.) 0.5993 g (concentration: 0) .5993 (w / v)%), sodium dihydrogen phosphate dihydrate (manufactured by Wako Pure Chemical Industries, Ltd.) 0.0528 g (concentration: 0.0528 (w / v)%), and tonicity agent Sodium chloride (Wako Pure Chemical Industries, Ltd.) 0.83 g (concentration: 0.83 (w / )%) Dissolved was added to prepare a contact lens composition. The prepared contact lens composition had a pH of 7.4.

Next, a commercially available omafilcon A lens (trade name: Pro Clear One Day, manufactured by Cooper Vision Co., Ltd.) was prepared. Next, this contact lens is taken out from the packaging container, and the taken out contact lens is washed with a phosphate buffer-containing physiological saline (filter sterilized), and then the contact lens is washed with a sufficient amount of phosphate buffer-containing physiological saline. It was immersed in water (filter sterilized) and left overnight.

Next, 2 ml of a vial (made of glass, volume 10 ml) sterilized by dry heat was filled with the above contact lens composition, and the contact lens taken out from the phosphate buffer-containing physiological saline was immersed therein. The vial was then sealed and stored at room temperature for 168 hours to produce a test contact lens.

(Comparative Example 4)
Test contact in the same manner as in Example 4 except that a composition containing no vinyl acetate-vinyl pyrrolidone copolymer and l-menthol was used instead of the prepared contact lens composition. A lens composition was prepared.

(Human wearing method)
Next, three healthy persons were allowed to wear the test contact lens prepared in Example 4 in the right eye and the test contact lens prepared in Comparative Example 4 in the left eye. On the next day, the same healthy person was worn with the test contact lens produced in Comparative Example 4 in the right eye and the test contact lens produced in Example 4 in the left eye.

(Usage evaluation)
Immediately after wearing, and 8 hours after wearing, using the VAS method (Visual Analogue Scale), the following evaluation items (feeling of dryness, feeling of catching on upper eyelid, feeling of catching on lower eyelid, feeling of catching on lower eyelid, lens The feeling of pulling up, the feeling of sticking the lens, and the feeling of foreign matter) were evaluated. Specifically, at the time of evaluation, for each of the evaluation items felt by the subject, the subjective symptom survey sheet with a 118 mm line drawn feels 0 mm when not felt, 59 mm when felt, and strongly felt. The case was set at 118 mm, and the symptom felt by the subject was checked, and the length (mm) was measured as the subjective symptom score, and this was used as the score for each symptom.

Evaluation was carried out for 2 days on the test day, and each symptom was evaluated by calculating the average score of 3 persons (6 eyes) for each evaluation item. Table 11 shows the above results.

(Friction test)
The coefficient of dynamic friction was determined for the test contact lens after the human had worn for 8 hours by the same method as Test 3 (friction test) described above. The results are shown in Table 12.

As shown in Table 11, Example 4 containing vinyl acetate-vinyl pyrrolidone copolymer and l-menthol was vinyl acetate-vinyl pyrrolidone both immediately after wearing and 8 hours after wearing. It can be seen that the subjective symptom score is lowered and the subjective symptom can be improved in all items to be evaluated as compared with Comparative Example 4 which does not contain a copolymer.

In particular, it can be seen that not only immediately after wearing but also after 8 hours of wearing, the deterioration of wearing feeling caused by wearing can be remarkably reduced and excellent wearing feeling can be maintained.

Furthermore, as shown in Table 12, when the friction was evaluated using a contact lens actually worn by a human, the friction on the contact lens surface was significantly improved (n = 6, P <0.05, paired t test). From this, it can be seen that even when a human wears a contact lens, friction is unlikely to occur for a long time, and an excellent wearing feeling can be maintained.

[Test 5: Evaluation of mucin expression in corneal epithelial cells]
Example 5-1
(Sample preparation)
A vinyl acetate-vinylpyrrolidone copolymer (manufactured by Osaka Organic Chemical Industry Co., Ltd., trade name: Acorn M, molecular weight of about 70,000) was adjusted to a concentration of 0.01 (w / v)% by DMEM / F12 (Invitrogen). ) Dissolved in the medium.

(Evaluation of mucin production)
Corneal epithelial cell line HCE-T (RIKEN BioResource Center) is seeded at 6 × 10 ⁵ plate (Corning) at 3.0 × 10 ⁵ cells / well, under conditions of 37 ° C., 5% CO ₂ and 90% humidity. Incubated until confluent.

Next, 2 ml of the sample prepared above was added to the cultured corneal epithelial cell line, and stored for 24 hours at 37 ° C., 5% CO ₂ , and 90% humidity.

Thereafter, total RNA in the cell was isolated using RNeasy Mini Kit (QIAGEN). Then, the mRNA expression level of the membrane type mucin (MUC16) was quantified by quantitative real-time PCR method using ABI PRISM7000 Sequence Detection System (Applied Biosystems). The above results are shown in Table 13.

(Example 5-2)
Vinyl acetate-vinyl pyrrolidone copolymer (manufactured by Osaka Organic Chemical Industry Co., Ltd., trade name: Acorn M, molecular weight of about 70000), concentration: 0.01 (w / v)%, l-menthol (concentration in DMSO in advance: 1 (W / V)%) was dissolved in DMEM / F12 (Invitrogen) medium so that the concentration of l-menthol was 0.0002 (W / V)%.

Using this sample, the mRNA expression level of membrane mucin (MUC16) was quantified in the same manner as in Example 5-1 described above. The above results are shown in Table 13.

(Example 5-3)
Vinyl acetate-vinyl pyrrolidone copolymer (manufactured by Osaka Organic Chemical Industry Co., Ltd., trade name: Acorn M, molecular weight of about 70,000), concentration: 0.01 (w / v)%, l-menthol (concentrated in DMSO in advance) : 1 (w / v)%) was dissolved in DMEM / F12 (Invitrogen) medium so that the concentration of l-menthol was 0.002 (w / v)%.

(Comparative Example 5)
Quantification of mRNA expression level of membrane mucin (MUC16) in the same manner as in Example 5-1, except that a corneal epithelial cell line containing no vinyl acetate-vinyl pyrrolidone copolymer and l-menthol was used. Went. The above results are shown in Table 13.

As shown in Table 13, the membrane type mucin in Example 5-1 containing the vinyl acetate-vinyl pyrrolidone copolymer was compared with Comparative Example 5 not containing the vinyl acetate-vinyl pyrrolidone copolymer. It can be seen that the expression level of is increased.

In addition, in Examples 5-2 to 5-3 containing vinyl acetate-vinyl pyrrolidone copolymer and l-menthol, it can be seen that the expression level of membrane-type mucin is dramatically increased.

[Test 6 Evaluation of contact lens clarity]
Example 6-1
To 100 g of sterilized purified water, 2 g of a vinyl acetate-vinylpyrrolidone copolymer (manufactured by BASF, trade name: Luviskol (registered trademark) VA73E, VP / VA ratio: 70/30, molecular weight of about 40000-60000) (concentration: 1 ( w / v)%), sodium hydrogen phosphate 12 hydrate as a buffering agent (manufactured by Wako Pure Chemical Industries, Ltd.) 0.5993 g (concentration: 0.5993 (w / v)%), sodium dihydrogen phosphate Dihydrate (manufactured by Wako Pure Chemical Industries, Ltd.) 0.0528 g (concentration: 0.0528 (w / v)%) and sodium chloride as an isotonic agent (manufactured by Wako Pure Chemical Industries, Ltd.) 83 g (concentration: 0.83 (w / v)%) was added and dissolved to prepare a contact lens composition. The prepared contact lens composition had a pH of 7.4.

Next, the contact lens is immersed in the contact lens composition to bring the contact lens into contact with the contact lens composition, and the contact lens and the contact lens composition are sealed and autoclaved (121 ° C., 20 Minutes) and left at room temperature for 120 hours. Thereafter, the contact lens was taken out and visually observed.

(Example 6-2)
2 g (concentration: 1 (w / v)%) of vinyl acetate-vinylpyrrolidone copolymer (manufactured by BASF, trade name: Luviskol (registered trademark) VA64P, VP / VA ratio: 60/40, molecular weight of about 50,000 to 60,000) Except for the use, the contact lens was treated in the same manner as in Example 6-1 above, and the state was visually observed.

(Example 6-3)
2 g (concentration: 1 (w / v)%) of vinyl acetate-vinylpyrrolidone copolymer (manufactured by BASF, trade name: Luviskol (registered trademark) VA55I, VP / VA ratio: 50/50, molecular weight of about 70,000 to 80,000) Except for the use, the contact lens was treated in the same manner as in Example 6-1 above, and the state was visually observed.

(Reference Test Example 6-1)
2 g (concentration: 1 (w / v)%) of vinyl acetate-vinylpyrrolidone copolymer (manufactured by BASF, trade name: Luviskol (registered trademark) VA37E, VP / VA ratio: 30/70, molecular weight of about 80,000 to 100,000) Except for the use, the contact lens was treated in the same manner as in Example 6-1 above, and the state was visually observed.

As shown in Table 14, when the contact lens compositions of Examples 6-1 to 6-3 were used, it was confirmed that the state of the contact lens was kept clear. On the other hand, in Reference Test Example 6-1, it was confirmed that the contact lens became cloudy.

As described above, the present invention is particularly useful for a contact lens composition used as a packaging solution enclosed in a packaging container together with a contact lens, and a contact lens package using the same.

1 Contact lens
2 Female mold
2a Concave
3 Male mold
3a Convex surface
4 Lens mold
5 Formulations for contact lenses
6 UV
7 Contact lens composition
8 Packaging containers

Claims

A composition for contact lenses containing a vinyl acetate-vinyl pyrrolidone copolymer.
The contact lens composition according to claim 1, wherein the vinyl acetate / vinyl pyrrolidone ratio in the vinyl acetate-vinyl pyrrolidone copolymer is 80/20 to 20/80.
3. The contact lens composition according to claim 1, wherein the concentration of the vinyl acetate-vinyl pyrrolidone copolymer is 0.0001 to 10 (w / v)%.
4. The contact lens composition according to claim 1, wherein the vinyl acetate-vinyl pyrrolidone copolymer has a weight average molecular weight of 5,000 to 500,000.
The contact lens composition according to claim 1, further comprising a terpenoid.
6. The terpenoid is at least one selected from the group consisting of menthol, menthone, camphor, borneol, geraniol, cineol, citronellol, carvone, anethole, eugenol, limonene, linalool and linalyl acetate. The composition for contact lenses of description.
The contact lens composition according to any one of claims 1 to 6, wherein the contact lens is a soft contact lens.
The contact lens composition according to any one of claims 1 to 7, wherein the composition is used as a packaging liquid for contact lenses.
A contact lens package in which the composition for contact lenses according to claim 8 is contained in a packaging container together with the contact lenses.
A contact lens packaged together with the contact lens composition according to claim 8 in a packaging container.
A method for inhibiting protein adhesion to a contact lens by immersing the contact lens in a composition for contact lens containing vinyl acetate-vinyl pyrrolidone.
A method for suppressing lipid adsorption on a contact lens by immersing the contact lens in a contact lens composition containing vinyl acetate-vinyl pyrrolidone.
A method of imparting a friction reducing action to the surface of the contact lens by immersing the contact lens in a contact lens composition containing vinyl acetate-vinyl pyrrolidone.
A method of imparting a moist feeling improving effect to the contact lens when the contact lens is worn by immersing the contact lens in a contact lens composition containing vinyl acetate-vinyl pyrrolidone.
A method for imparting a dry feeling-reducing action to the contact lens by immersing the contact lens in a contact lens composition containing vinyl acetate-vinyl pyrrolidone.
A method for imparting an effect of reducing discomfort during wearing of the contact lens by immersing the contact lens in a contact lens composition containing vinyl acetate-vinyl pyrrolidone.